Cell and gene therapy manufacturing specialist AGC Biologics is continuing its rapid expansion and has added three new production suites to its site in Longmont, Colorado.
News of the expansion comes two weeks after the Seattle-based CDMO said it had completed a major upgrade of its cell and gene therapy site in Milan, Italy.
AGC’s Longmont upgrades, which were revealed in May of last year as a $30 million-plus investment, include two new process suites and one flex suite. The plant, which was acquired from Novartis in August of 2021, becomes AGC’s first site in North America that can support cell and gene therapy manufacturing at any stage, the company said.
The expansion brings more than 30,000 square feet of added floor space and “is the final piece for this campus that complements our comprehensive viral vector capabilities and gives developers a true end-to-end manufacturing site,” Whitney Sandberg, general manager of the site, said in a release.
AGC has the capability to expand the site by nine more cell therapy suites “to meet additional market demand," the company said.
The company's sudden expansion in cell and gene therapy manufacturing began in 2020 when it acquired Italian company MolMed.
AGC recently finished off a 27,000-square-foot expansion of the Milan site, which it gained in the MolMed purchase.
AGC has supported four commercial viral vector products, three commercial cell therapies and more than 30 cell and gene therapy clinical trials across Europe and the U.S.